TrialArthritis research & therapy2012

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

Dona L Fleishaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.